FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Lloyd Kelland

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Procedures

Drug Screening Assays, Antitumor

Living Beings

Physiology

Concepts & Ideas

Structure-Activity Relationship

Co-author Network

Publications

TOP 3
Paul Workman; Eric O Aboagye; Frances R Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; Lloyd R Kelland; V Robinson; I J Stratford; Gillian M Tozer; S Watson; S R Wedge; Suzanne A Eccles
Guidelines for the welfare and use of animals in cancer research.
Mekala Gunaratnam; Colin Green; Joao Moreira; Adam D Moorhouse; Lloyd R Kelland; John E Moses; Stephen Neidle
G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo.
Alexander Hegmans; Jana Kasparkova; Oldrich Vrana; Lloyd R Kelland; Viktor Brabec; Nicholas Farrell
Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Lloyd Kelland (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Paul Workman; Eric O Aboagye; Frances R Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; Lloyd R Kelland; V Robinson; I J Stratford; Gillian M Tozer; S Watson; S R Wedge; Suzanne A Eccles
Guidelines for the welfare and use of animals in cancer research.
British journal of cancer 2010;102(11):1555-77.
2009: Mekala Gunaratnam; Colin Green; Joao Moreira; Adam D Moorhouse; Lloyd R Kelland; John E Moses; Stephen Neidle
G-quadruplex compounds and cis-platin act synergistically to inhibit cancer cell growth in vitro and in vivo.
Biochemical pharmacology 2009;78(2):115-22.
2008: Alexander Hegmans; Jana Kasparkova; Oldrich Vrana; Lloyd R Kelland; Viktor Brabec; Nicholas Farrell
Amide-based prodrugs of spermidine-bridged dinuclear platinum. Synthesis, DNA binding, and biological activity.
Journal of medicinal chemistry 2008;51(7):2254-60.
2007: Lloyd R Kelland
Targeting the limitless replicative potential of cancer: the telomerase/telomere pathway.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(17):4960-3.
2007: Lloyd R Kelland
The resurgence of platinum-based cancer chemotherapy.
Nature reviews. Cancer 2007;7(8):573-84.
2007: Lloyd R Kelland
Broadening the clinical use of platinum drug-based chemotherapy with new analogues. Satraplatin and picoplatin.
Expert opinion on investigational drugs 2007;16(7):1009-21.
2007: Laura Martelli; Francesco Di Mario; Paolo Botti; Eugenio Ragazzi; Maurizio Martelli; Lloyd R Kelland
Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Biochemical pharmacology 2007;74(1):20-7.
2007: Florence I Raynaud; Suzanne A Eccles; Paul A Clarke; Angela Hayes; Bernard P Nutley; Sonia Alix; Alan Henley; Francesca Di-Stefano; Zahida Ahmad; Sandrine Guillard; Lynn M Bjerke; Lloyd R Kelland; Melanie Valenti; Lisa Patterson; Sharon M Gowan; Alexis de Haven Brandon; Masahiko Hayakawa; Hiroyuki Kaizawa; Tomonubu Koizumi; Takahide Ohishi; Sonal Patel; Nahid Saghir; Peter Parker; Michael D Waterfield; Paul Workman
Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases.
Cancer research 2007;67(12):5840-50.
2007: Liangli Zhao; Elaine S Marshall; Lloyd R Kelland; Bruce C Baguley
Evidence for the involvement of p38 MAP kinase in the action of the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Investigational new drugs 2007;25(3):271-6.
2007: Cristina Martins; Mekala Gunaratnam; John Stuart; Vaidahi Makwana; Olga Greciano; Anthony P Reszka; Lloyd R Kelland; Stephen Neidle
Structure-based design of benzylamino-acridine compounds as G-quadruplex DNA telomere targeting agents.
Bioorganic & medicinal chemistry letters 2007;17(8):2293-8.
2007: Lloyd R Kelland
Drug evaluation: ADH-1, an N-cadherin antagonist targeting cancer vascularization.
Current opinion in molecular therapeutics 2007;9(1):86-91.
2006: Christopher R Ireson; Lloyd R Kelland
Discovery and development of anticancer aptamers.
Molecular cancer therapeutics 2006;5(12):2957-62.
2006: Lloyd R Kelland
Discontinued drugs in 2005: oncology drugs.
Expert opinion on investigational drugs 2006;15(11):1309-18.
2006: Lesley D McPhail; Dominick J O McIntyre; Christian Ludwig; Philip Kestell; John R Griffiths; Lloyd R Kelland; Simon P Robinson
Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
Neoplasia (New York, N.Y.) 2006;8(3):199-206.
2006: Lloyd R Kelland
EuroTIDES 2005--Sixth Annual IBC Conference.
IDrugs : the investigational drugs journal 2006;9(2):101-4.
2006: Kathryn Nicoll; Jane Robertson; Neil Lant; Lloyd R Kelland; Paul M Rogers; David J Robins
Synthesis and antimelanoma activity of reversed amide analogues of N-acetyl-4-S-cysteaminylphenol.
Oncology research 2006;16(2):97-106.
2005: Amanda L Harris; Xiaohong Yang; Alexander Hegmans; Lawrence F Povirk; John J Ryan; Lloyd R Kelland; Nicholas Farrell
Synthesis, characterization, and cytotoxicity of a novel highly charged trinuclear platinum compound. Enhancement of cellular uptake with charge.
Inorganic chemistry 2005;44(26):9598-600.
2005: Bernard P Nutley; Nicola F Smith; Angela Hayes; Lloyd R Kelland; Lisa Brunton; Bernard T Golding; G C M Smith; Niall M B Martin; Paul Workman; Florence I Raynaud
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026.
British journal of cancer 2005;93(9):1011-8.
2005: Udai Banerji; Michael Walton; Florence I Raynaud; Rachel Grimshaw; Lloyd R Kelland; Melanie Valenti; Ian Judson; Paul Workman
Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):7023-32.
2005: Erin S F Ma; W Douglas Bates; Armistead Edmunds; Lloyd R Kelland; Tito Fojo; Nicholas Farrell
Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile.
Journal of medicinal chemistry 2005;48(18):5651-4.
2005: Liangli Zhao; Lai-Ming Ching; Philip Kestell; Lloyd R Kelland; Bruce C Baguley
Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
International journal of cancer. Journal international du cancer 2005;116(2):322-6.
2005: Florence I Raynaud; Steven R Whittaker; Peter M Fischer; Steven McClue; Mike I Walton; S Elaine Barrie; Michelle D Garrett; Paul Rogers; Simon J Clarke; Lloyd R Kelland; Melanie Valenti; Lisa Brunton; Suzanne A Eccles; David P Lane; Paul Workman
In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4875-87.
2005: Lesley D McPhail; Yuen-Li Chung; Basetti Madhu; Simon Clark; John R Griffiths; Lloyd R Kelland; Simon P Robinson
Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(10):3705-13.
2005: Lloyd R Kelland
Emerging drugs for ovarian cancer.
Expert opinion on emerging drugs 2005;10(2):413-24.
2005: Lloyd R Kelland
Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics--current status and future prospects.
European journal of cancer (Oxford, England : 1990) 2005;41(7):971-9.
2005: Jillian Ferguson; Paul M Rogers; Lloyd R Kelland; David J Robins
Synthesis and antimelanoma activity of sterically congested tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol.
Oncology research 2005;15(2):87-94.
2004: R John Harrison; Anthony P Reszka; haider shozeb; Barbara Romagnoli; James Morrell; Martin A Read; Sharon M Gowan; Christopher M Incles; Lloyd R Kelland; Stephen Neidle
Evaluation of by disubstituted acridone derivatives as telomerase inhibitors: the importance of G-quadruplex binding.
Bioorganic & medicinal chemistry letters 2004;14(23):5845-9.
2004: Christopher M Incles; Christoph Schultes; Helena Kempski; Heike Koehler; Lloyd R Kelland; Stephen Neidle
A G-quadruplex telomere targeting agent produces p16-associated senescence and chromosomal fusions in human prostate cancer cells.
Molecular cancer therapeutics 2004;3(10):1201-6.
2004: John A Hartley; Victoria J Spanswick; Natalie A Brooks; Peter H Clingen; Peter J McHugh; Daniel Hochhauser; R Barbara Pedley; Lloyd R Kelland; Michael C Alley; Robert Schultz; Melinda G Hollingshead; Karen M Schweikart; Joseph E Tomaszewski; Edward A Sausville; Stephen J Gregson; Philip W Howard; David E Thurston
SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Cancer research 2004;64(18):6693-9.
2004: Lloyd R Kelland
Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
European journal of cancer (Oxford, England : 1990) 2004;40(6):827-36.
2004: Klaus Pors; Zennia Paniwnyk; Ketan Chatrabhuj Ruparelia; Paul Teesdale-Spittle; John A Hartley; Lloyd R Kelland; Laurence H Patterson
Synthesis and biological evaluation of novel chloroethylaminoanthraquinones with potent cytotoxic activity against cisplatin-resistant tumor cells.
Journal of medicinal chemistry 2004;47(7):1856-9.
2004: Athanasia Varvaresou; Kritonas Iakovou; Evagelos Gikas; Iduna Fichtner; Heinz-Herbert Fiebig; Lloyd R Kelland; John A Double; Michael C Bibby; HR Hendriks
Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Anticancer research 2004;24(2B):907-19.
2004: LR Hiorns; T D Bradshaw; L A Skelton; Q Yu; Lloyd R Kelland; Brian Leyland-Jones
Variation in RNA expression and genomic DNA content acquired during cell culture.
British journal of cancer 2004;90(2):476-82.
2004: Beatrice Seddon; Lloyd R Kelland; Paul Workman
Bioreductive prodrugs for cancer therapy.
Methods in molecular medicine 2004;90():515-42.
2003: Christopher M Incles; Christoph Schultes; Lloyd R Kelland; Stephen Neidle
Acquired cellular resistance to flavopiridol in a human colon carcinoma cell line involves up-regulation of the telomerase catalytic subunit and telomere elongation. Sensitivity of resistant cells to combination treatment with a telomerase inhibitor.
Molecular pharmacology 2003;64(5):1101-8.
2003: R John Harrison; Javier Cuesta; Gianni Chessari; Martin A Read; Sanji K Basra; Anthony P Reszka; James Morrell; Sharon M Gowan; Christopher M Incles; Farial A Tanious; David W. Wilson; Lloyd R Kelland; Stephen Neidle
Trisubstituted acridine derivatives as potent and selective telomerase inhibitors.
Journal of medicinal chemistry 2003;46(21):4463-76.
2003: Stephen R D Johnston; Tamas Hickish; Paul Ellis; Stephen Houston; Lloyd R Kelland; Mitch Dowsett; Janine Salter; Bart Michiels; Juan Jose Perez-Ruixo; Peter Palmer; Angela Howes
Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2492-9.
2003: Michael D Urbaniak; Lisa M Frost; John P Bingham; Lloyd R Kelland; John A Hartley; Derek N Woolfson; Stephen Caddick
Chemical synthesis and cytotoxicity of dihydroxylated cyclopentenone analogues of neocarzinostatin chromophore.
Bioorganic & medicinal chemistry letters 2003;13(12):2025-7.
2003: José M Pérez; Lloyd R Kelland; Eva Montero; Frances E Boxall; Miguel A Fuertes; Carlos Alonso; Carmen Navarro-Ranninger
Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)].
Molecular pharmacology 2003;63(4):933-44.
2003: Lloyd R Kelland
Farnesyl transferase inhibitors in the treatment of breast cancer.
Expert opinion on investigational drugs 2003;12(3):413-21.
2003: Vikki C Pearson; Jillian Ferguson; Paul M Rogers; Lloyd R Kelland; David J Robins
Synthesis and antimelanoma activity of tertiary amide analogues of N-acetyl-4-S-cysteaminylphenol.
Oncology research 2003;13(11):503-12.
2002: SY Sharp; CF O'Neill; P Rogers; Frances E Boxall; Lloyd R Kelland
Retention of activity by the new generation platinum agent AMD0473 in four human tumour cell lines possessing acquired resistance to oxaliplatin.
European journal of cancer (Oxford, England : 1990) 2002;38(17):2309-15.
2002: Marilena Vlachou; Andrew Tsotinis; Lloyd R Kelland; David E Thurston
An expeditious synthesis of cytotoxic pyrroloisoquinoline derivatives. Structure-activity comparative studies with isomeric pyrroloquinolines.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2002;17(3):139-43.
2002: P Rogers; Frances E Boxall; C P Allott; T C Stephens; Lloyd R Kelland
Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1653-60.
2002: Vicki Smith; Stephen Hobbs; William Court; Suzanne A Eccles; Paul Workman; Lloyd R Kelland
ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin.
Anticancer research 2002;22(4):1993-9.
2002: Victoria Smith; Martin G Rowlands; Elaine Barrie; Paul Workman; Lloyd R Kelland
Establishment and characterization of acquired resistance to the farnesyl protein transferase inhibitor R115777 in a human colon cancer cell line.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(6):2002-9.
2002: Jane M Berry; Philip W Howard; Lloyd R Kelland; David E Thurston
Synthesis and biological evaluation of an N10-Psec substituted pyrrolo[2,1-c][1,4]benzodiazepine prodrug.
Bioorganic & medicinal chemistry letters 2002;12(10):1413-6.
2002: Sharon M Gowan; John R Harrison; Lisa Patterson; Melanie Valenti; Martin A Read; Stephen Neidle; Lloyd R Kelland
A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity.
Molecular pharmacology 2002;61(5):1154-62.
2002: Paul M Rogers; Philip Beale; Mansour S Al-Moundhri; Frances E Boxall; Lisa Patterson; Melanie Valenti; Florence I Raynaud; Steve Hobbs; Stephen Johnston; Lloyd R Kelland
Overexpression of BclXL in a human ovarian carcinoma cell line: paradoxic effects on chemosensitivity in vitro versus in vivo.
International journal of cancer. Journal international du cancer 2002;97(6):858-63.
2002: Robert A Heald; Chetna Modi; Jennifer C Cookson; Ian Hutchinson; Charles A Laughton; Sharon M Gowan; Lloyd R Kelland; Malcolm F G Stevens
Antitumor polycyclic acridines. 8.(1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts.
Journal of medicinal chemistry 2002;45(3):590-7.
2001: HA Cocker; SM Hobbs; Nicki Tiffin; Kathy Pritchard-Jones; CR Pinkerton; Lloyd R Kelland
High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance.
British journal of cancer 2001;85(11):1746-52.
2001: Alexander Hegmans; Yun Qu; Lloyd R Kelland; John D Roberts; Nicholas Farrell
Novel approaches to polynuclear platinum pro-drugs. Selective release of cytotoxic platinum-spermidine species through hydrolytic cleavage of carbamates.
Inorganic chemistry 2001;40(24):6108-14.
2001: Stephen J Gregson; Philip W Howard; Kathryn E Corcoran; Terence C Jenkins; Lloyd R Kelland; David E Thurston
Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer.
Bioorganic & medicinal chemistry letters 2001;11(21):2859-62.
2001: Lloyd R Kelland; V Smith; Melanie Valenti; Lisa Patterson; Paul A Clarke; S Detre; D End; Angela Howes; Mitch Dowsett; Paul Workman; Stephen R D Johnston
Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(11):3544-50.
2001: HA Cocker; Nicki Tiffin; Kathy Pritchard-Jones; CR Pinkerton; Lloyd R Kelland
In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(10):3193-8.
2001: John R Masters; Jim A Thomson; B Daly-Burns; Yael Reid; Wilhelm G Dirks; P Packer; L H Toji; T Ohno; H Tanabe; Colin F Arlett; Lloyd R Kelland; M Harrison; A Virmani; Tim Ward; KL Ayres; Paul G Debenham
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(14):8012-7.
2001: M Read; R John Harrison; B Romagnoli; Farial A Tanious; S H Gowan; Anthony P Reszka; David W. Wilson; Lloyd R Kelland; Stephen Neidle
Structure-based design of selective and potent G quadruplex-mediated telomerase inhibitors.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(9):4844-9.
2001: Stephen J Gregson; Philip W Howard; John A Hartley; Natalie A Brooks; L J Adams; Terence C Jenkins; Lloyd R Kelland; David E Thurston
Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.
Journal of medicinal chemistry 2001;44(5):737-48.
2001: Neil Lant; P McKeown; M C Timoney; Lloyd R Kelland; Paul M Rogers; David J Robins
Synthesis and anti-melanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol substituted with two methyl groups alpha to the nitrogen.
Anti-cancer drug design 2001;16(1):49-55.
2000: Ippolito Antonini; Paolo Polucci; Lloyd R Kelland; S Spinelli; Nicoletta Pescalli; Sante Martelli
N4-(omega-Aminoalkyl)-1-[(omega-aminoalkyl)amino]-4- acridinecarboxamides: novel, potent, cytotoxic, and DNA-binding agents.
Journal of medicinal chemistry 2000;43(25):4801-5.
2000: Lloyd R Kelland
Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.
Expert opinion on investigational drugs 2000;9(12):2903-11.
2000: SY Sharp; Lloyd R Kelland; Melanie Valenti; L A Brunton; SM Hobbs; Paul Workman
Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.
Molecular pharmacology 2000;58(5):1146-55.
2000: J Holford; Philip Beale; Frances E Boxall; SY Sharp; Lloyd R Kelland
Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines.
European journal of cancer (Oxford, England : 1990) 2000;36(15):1984-90.
2000: Stephen J Gregson; Philip W Howard; S Barcella; A Nakamya; Terence C Jenkins; Lloyd R Kelland; David E Thurston
Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines.
Bioorganic & medicinal chemistry letters 2000;10(16):1849-51.
2000: Stephen J Gregson; Philip W Howard; Kathryn E Corcoran; S Barcella; M M Yasin; A A Hurst; Terence C Jenkins; Lloyd R Kelland; David E Thurston
Effect of C2-exo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines.
Bioorganic & medicinal chemistry letters 2000;10(16):1845-7.
2000: Yun Qu; H Rauter; A P Soares Fontes; R Bandarage; Lloyd R Kelland; Nicholas Farrell
Synthesis, characterization, and cytotoxicity of trifunctional dinuclear platinum complexes: comparison of effects of geometry and polyfunctionality on biological activity.
Journal of medicinal chemistry 2000;43(16):3189-92.
2000: Neil Lant; P McKeown; Lloyd R Kelland; Paul M Rogers; David J Robins
Synthesis and antimelanoma activity of analogues of N-acetyl-4-S-cysteaminylphenol.
Anti-cancer drug design 2000;15(4):295-302.
2000: HA Cocker; CR Pinkerton; Lloyd R Kelland
Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines.
British journal of cancer 2000;83(3):338-45.
2000: Carla Manzotti; Graziella Pratesi; Ernesto Menta; R Di Domenico; Ennio Cavalletti; H H Fiebig; Lloyd R Kelland; Nicholas Farrell; D Polizzi; Rosanna Supino; Gabriella Pezzoni; Franco Zunino
BBR 3464: a novel triplatinum complex, exhibiting a preclinical profile of antitumor efficacy different from cisplatin.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2626-34.
2000: Lloyd R Kelland
An update on satraplatin: the first orally available platinum anticancer drug.
Expert opinion on investigational drugs 2000;9(6):1373-82.
2000: KE Pestell; S M Hobbs; Jenny Titley; Lloyd R Kelland; Mike I Walton
Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line.
Molecular pharmacology 2000;57(3):503-11.
2000: I Judson; Lloyd R Kelland
New developments and approaches in the platinum arena.
Drugs 2000;59 Suppl 4():29-36; discussion 37-8.
2000: Lloyd R Kelland
Preclinical perspectives on platinum resistance.
Drugs 2000;59 Suppl 4():1-8; discussion 37-8.
2000: Philip Beale; P Rogers; Frances E Boxall; SY Sharp; Lloyd R Kelland
BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma.
British journal of cancer 2000;82(2):436-40.
1999: CF O'Neill; B Koberle; J R Masters; Lloyd R Kelland
Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
British journal of cancer 1999;81(8):1294-303.
1999: Lloyd R Kelland; SY Sharp; Paul M Rogers; Timothy G Myers; Paul Workman
DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90.
Journal of the National Cancer Institute 1999;91(22):1940-9.
1999: CF O'Neill; L Hunakova; Lloyd R Kelland
Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
Chemico-biological interactions 1999;123(1):11-29.
1999: Martin A Read; AA Wood; J R Harrison; Sharon M Gowan; Lloyd R Kelland; HS Dosanjh; Stephen Neidle
Molecular modeling studies on G-quadruplex complexes of telomerase inhibitors: structure-activity relationships.
Journal of medicinal chemistry 1999;42(22):4538-46.
1999: S C Wilson; Philip W Howard; S M Forrow; John A Hartley; L J Adams; Terence C Jenkins; Lloyd R Kelland; David E Thurston
Design, synthesis, and evaluation of a novel sequence-selective epoxide-containing DNA cross-linking agent based on the pyrrolo[2, 1-c][1,4]benzodiazepine system.
Journal of medicinal chemistry 1999;42(20):4028-41.
1999: Lloyd R Kelland
Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy.
Journal of inorganic biochemistry 1999;77(1-2):121-4.
1999: Lloyd R Kelland; SY Sharp; CF O'Neill; Florence I Raynaud; Philip Beale; Ian R Judson
Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Journal of inorganic biochemistry 1999;77(1-2):111-5.
1999: LR Hiorns; Michael J Seckl; Fernando J Paradinas; SY Sharp; L A Skelton; G Brunstrom; Edward S Newlands; Lloyd R Kelland; Brian Leyland-Jones
A molecular cytogenetic approach to studying platinum resistance.
Journal of inorganic biochemistry 1999;77(1-2):95-104.
1999: R John Harrison; Sharon M Gowan; Lloyd R Kelland; Stephen Neidle
Human telomerase inhibition by substituted acridine derivatives.
Bioorganic & medicinal chemistry letters 1999;9(17):2463-8.
1999: PJ Perry; Sharon M Gowan; Martin A Read; Lloyd R Kelland; Stephen Neidle
Design, synthesis and evaluation of human telomerase inhibitors based upon a tetracyclic structural motif.
Anti-cancer drug design 1999;14(4):373-82.
1999: PJ Perry; Martin A Read; R T Davies; Sharon M Gowan; Anthony P Reszka; AA Wood; Lloyd R Kelland; Stephen Neidle
2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase.
Journal of medicinal chemistry 1999;42(14):2679-84.
1999: Ippolito Antonini; Paolo Polucci; Lloyd R Kelland; Ernesto Menta; Nicoletta Pescalli; Sante Martelli
2,3-Dihydro-1H,7H-pyrimido[5,6,1-de]acridine-1,3,7-trione derivatives, a class of cytotoxic agents active on multidrug-resistant cell lines: synthesis, biological evaluation, and structure-activity relationships.
Journal of medicinal chemistry 1999;42(14):2535-41.
1999: Brian Leyland-Jones; Lloyd R Kelland; K R Harrap; LR Hiorns
Genomic imbalances associated with acquired resistance to platinum analogues.
The American journal of pathology 1999;155(1):77-84.
1999: David E Thurston; D S Bose; Philip W Howard; Terence C Jenkins; A Leoni; Pier Giovanni Baraldi; Andrea Guiotto; Barbara Cacciari; Lloyd R Kelland; M P Foloppe; S Rault
Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines.
Journal of medicinal chemistry 1999;42(11):1951-64.
1999: Lloyd R Kelland
Small molecule anticancer drugs.
IDrugs : the investigational drugs journal 1999;2(6):550-2.
1999: Jose M Perez; M Camazón; A Alvarez-Valdes; Adoracion Quiroga; Lloyd R Kelland; Carlos Alonso; M C Navarro-Ranninger
Synthesis, characterization and DNA modification induced by a novel Pt(IV)-bis(monoglutarate) complex which induces apoptosis in glioma cells.
Chemico-biological interactions 1999;117(2):99-115.
1999: Lloyd R Kelland; Philip Beale
Bcl-2 family immunohistochemistry.
Methods in molecular medicine 1999;28():201-8.
1998: PJ Perry; Anthony P Reszka; AA Wood; Martin A Read; Sharon M Gowan; HS Dosanjh; John O Trent; TC Jenkins; Lloyd R Kelland; Stephen Neidle
Human telomerase inhibition by regioisomeric disubstituted amidoanthracene-9,10-diones.
Journal of medicinal chemistry 1998;41(24):4873-84.
1998: N D Henderson; Stephen M Lacy; C Caroline O'Hare; John A Hartley; S McClean; LP Wakelin; Lloyd R Kelland; David J Robins
Synthesis of new bifunctional compounds which selectively alkylate guanines in DNA.
Anti-cancer drug design 1998;13(7):749-68.
1998: KE Pestell; C J Medlow; Jenny Titley; Lloyd R Kelland; Mike I Walton
Characterisation of the p53 status, BCL-2 expression and radiation and platinum drug sensitivity of a panel of human ovarian cancer cell lines.
International journal of cancer. Journal international du cancer 1998;77(6):913-8.
1998: PJ Perry; Sharon M Gowan; Anthony P Reszka; Paolo Polucci; TC Jenkins; Lloyd R Kelland; Stephen Neidle
1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase.
Journal of medicinal chemistry 1998;41(17):3253-60.
1998: Lloyd R Kelland
DNA-interactive agents.
IDrugs : the investigational drugs journal 1998;1(4):397-8.
1998: Lloyd R Kelland
Signal transduction pathways.
IDrugs : the investigational drugs journal 1998;1(4):394-6.
1998: Lloyd R Kelland
NCI-EORTC--10th Symposium--new approaches and cellular targets. 16-19 June 1998, Amsterdam, The Netherlands.
IDrugs : the investigational drugs journal 1998;1(4):391-3.
1998: Tracey D Bradshaw; DF Shi; R J Schultz; K D Paull; Lloyd R Kelland; A Wilson; C Garner; H H Fiebig; S Wrigley; Malcolm F G Stevens
Influence of 2-(4-aminophenyl)benzothiazoles on growth of human ovarian carcinoma cells in vitro and in vivo.
British journal of cancer 1998;78(4):421-9.
1998: J Holford; P Rogers; Lloyd R Kelland
ras mutation and platinum resistance in human ovarian carcinomas in vitro.
International journal of cancer. Journal international du cancer 1998;77(1):94-100.
1998: SY Sharp; V Smith; SM Hobbs; Lloyd R Kelland
Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
British journal of cancer 1998;78(2):175-80.
1998: J Holford; Florence I Raynaud; BA Murrer; Keith A Grimaldi; John A Hartley; M Abrams; Lloyd R Kelland
Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum(II) (AMD473).
Anti-cancer drug design 1998;13(1):1-18.
1998: J Holford; SY Sharp; BA Murrer; M Abrams; Lloyd R Kelland
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473.
British journal of cancer 1998;77(3):366-73.
1997: Ippolito Antonini; Paolo Polucci; TC Jenkins; Lloyd R Kelland; Ernesto Menta; Nicoletta Pescalli; Barbara Stefanska; Jan Mazerski; Sante Martelli
1-[(omega-aminoalkyl)amino]-4-[N-(omega-aminoalkyl)carbamoyl]-9-oxo-9, 10-dihydroacridines as intercalating cytotoxic agents: synthesis, DNA binding, and biological evaluation.
Journal of medicinal chemistry 1997;40(23):3749-55.
1997: Florence I Raynaud; Frances E Boxall; Phyllis M Goddard; Melanie Valenti; M Jones; BA Murrer; M Abrams; Lloyd R Kelland
cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(11):2063-74.
1997: Mark J McKeage; Florence I Raynaud; J Ward; C Berry; D O'Dell; Lloyd R Kelland; BA Murrer; P Santabárabara; K R Harrap; I R Judson
Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(7):2691-700.
1997: Beate Köberle; Keith A Grimaldi; A Sunters; John A Hartley; Lloyd R Kelland; John R Masters
DNA repair capacity and cisplatin sensitivity of human testis tumour cells.
International journal of cancer. Journal international du cancer 1997;70(5):551-5.
1997: John R Masters; R J Know; John A Hartley; Lloyd R Kelland; HR Hendriks; T Connors
KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl]mitomycin C). A new mitomycin C analogue activated by serum.
Biochemical pharmacology 1997;53(3):279-85.
1996: R G Buckley; A M Elsome; Simon P Fricker; G R Henderson; B R Theobald; R V Parish; B P Howe; Lloyd R Kelland
Antitumor properties of some 2-[(dimethylamino)methyl]phenylgold(III) complexes.
Journal of medicinal chemistry 1996;39(26):5208-14.
1996: M G Ormerod; R M Orr; CF O'Neill; T Chwalinski; J C Titley; Lloyd R Kelland; K R Harrap
The cytotoxic action of four ammine/amine platinum(IV) dicarboxylates: a flow cytometric study.
British journal of cancer 1996;74(12):1935-43.
1996: CF O'Neill; M G Ormerod; D Robertson; J C Titley; Y Cumber-Walsweer; Lloyd R Kelland
Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine)dihydroxodichloroplatinum(IV) complex.
British journal of cancer 1996;74(7):1037-45.
1996: Florence I Raynaud; D E Odell; Lloyd R Kelland
Intracellular metabolism of the orally active platinum drug JM216: influence of glutathione levels.
British journal of cancer 1996;74(3):380-6.
1996: Florence I Raynaud; F E Boxall; P Goddard; C F Barnard; BA Murrer; Lloyd R Kelland
Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
Anticancer research 1996;16(4A):1857-62.
1996: Mike I Walton; P Goddard; Lloyd R Kelland; D E Thurston; K R Harrap
Preclinical pharmacology and antitumour activity of the novel sequence-selective DNA minor-groove cross-linking agent DSB-120.
Cancer chemotherapy and pharmacology 1996;38(5):431-8.
1996: G Wynne Aherne; Anthea Hardcastle; M Valenti; A Bryant; P Rogers; George R Pettit; J K Srirangam; Lloyd R Kelland
Antitumour evaluation of dolastatins 10 and 15 and their measurement in plasma by radioimmunoassay.
Cancer chemotherapy and pharmacology 1996;38(3):225-32.
1996: Florence I Raynaud; P Mistry; A Donaghue; G K Poon; Lloyd R Kelland; C F Barnard; BA Murrer; K R Harrap
Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Cancer chemotherapy and pharmacology 1996;38(2):155-62.
1996: Phyllis M Goddard; R M Orr; M R Valenti; C F Barnard; BA Murrer; Lloyd R Kelland; K R Harrap
Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Anticancer research 1996;16(1):33-8.
1995: G K Poon; Florence I Raynaud; P Mistry; D E Odell; Lloyd R Kelland; K R Harrap; C F Barnard; BA Murrer
Metabolic studies of an orally active platinum anticancer drug by liquid chromatography-electrospray ionization mass spectrometry.
Journal of chromatography. A 1995;712(1):61-6.
1995: K J Mellish; C F Barnard; BA Murrer; Lloyd R Kelland
DNA-binding properties of novel cis- and trans platinum-based anticancer agents in 2 human ovarian carcinoma cell lines.
International journal of cancer. Journal international du cancer 1995;62(6):717-23.
1995: SY Sharp; P M Rogers; Lloyd R Kelland
Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(9):981-9.
1995: Lloyd R Kelland; C F Barnard; I G Evans; BA Murrer; B R Theobald; S B Wyer; Phyllis M Goddard; M Jones; M Valenti; A Bryant
Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Journal of medicinal chemistry 1995;38(16):3016-24.
1995: Lloyd R Kelland; Rosemary Kimbell; Anthea Hardcastle; G Wynne Aherne; Ann L Jackman
Relationships between resistance to cisplatin and antifolates in sensitive and resistant tumour cell lines.
European journal of cancer (Oxford, England : 1990) 1995;31A(6):981-6.
1995: Ann L Jackman; Lloyd R Kelland; Rosemary Kimbell; M Brown; W Gibson; G Wynne Aherne; Anthea Hardcastle; F Thomas Boyle
Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.
British journal of cancer 1995;71(5):914-24.
1995: Mark J McKeage; P Mistry; J Ward; F E Boxall; S Loh; C O'Neill; P Ellis; Lloyd R Kelland; S E Morgan; BA Murrer
A phase I and pharmacology study of an oral platinum complex, JM216: dose-dependent pharmacokinetics with single-dose administration.
Cancer chemotherapy and pharmacology 1995;36(6):451-8.
1994: K J Mellish; Lloyd R Kelland
Mechanisms of acquired resistance to the orally active platinum-based anticancer drug bis-acetato-ammine-dichloro-cyclohexylamine platinum (i.v.) (JM216) in two human ovarian carcinoma cell lines.
Cancer research 1994;54(23):6194-200.
1994: Lloyd R Kelland; C F Barnard; K J Mellish; M Jones; Phyllis M Goddard; M Valenti; A Bryant; BA Murrer; K R Harrap
A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Cancer research 1994;54(21):5618-22.
1994: K J Mellish; C F Barnard; Lloyd R Kelland; K R Harrap
Circumvention of acquired tetraplatin resistance in a human ovarian carcinoma cell line by a novel trans platinum complex, JM335 [trans ammine (cyclohexylamine) dichloro dihydroxo platinum (IV)].
International journal of cancer. Journal international du cancer 1994;59(1):65-70.
1994: SY Sharp; Martin G Rowlands; Michael Jarman; Lloyd R Kelland
Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
British journal of cancer 1994;70(3):409-14.
1994: Mark J McKeage; Lloyd R Kelland; F E Boxall; M R Valenti; M Jones; Phyllis M Goddard; J Gwynne; K R Harrap
Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
Cancer research 1994;54(15):4118-22.
1994: Lloyd R Kelland; Mark J McKeage
New platinum agents. A comparison in ovarian cancer.
Drugs & aging 1994;5(2):85-95.
1994: P Goddard; M Valenti; Lloyd R Kelland
The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Anticancer research 1994;14(3A):1065-70.
1994: Mark J McKeage; G Abel; Lloyd R Kelland; K R Harrap
Mechanism of action of an orally administered platinum complex [ammine bis butyrato cyclohexylamine dichloroplatinum (IV) (JM221)] in intrinsically cisplatin-resistant human ovarian carcinoma in vitro.
British journal of cancer 1994;69(1):1-7.
1994: Florence I Raynaud; Lloyd R Kelland; M I Walton; I R Judson
Preclinical pharmacology of 1069C85, a novel tubulin binder.
Cancer chemotherapy and pharmacology 1994;35(2):169-73.
1994: SY Sharp; P Mistry; M R Valenti; A P Bryant; Lloyd R Kelland
Selective potentiation of platinum drug cytotoxicity in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines by amphotericin B.
Cancer chemotherapy and pharmacology 1994;35(2):137-43.
1994: Lloyd R Kelland
The molecular basis of cisplatin sensitivity/resistance.
European journal of cancer (Oxford, England : 1990) 1994;30A(6):725-7.
1994: Wynne Aherne; Anthea Hardcastle; Lloyd R Kelland; A Jackman
The measurement of deoxynucleotide (dNTP) pools by radioimmunoassay (RIA).
Advances in experimental medicine and biology 1994;370():801-4.
1993: Lloyd R Kelland
New platinum antitumor complexes.
Critical reviews in oncology/hematology 1993;15(3):191-219.
1993: P Mistry; S Y Loh; Lloyd R Kelland; K R Harrap
Effect of buthionine sulfoximine on PtII and PtIV drug accumulation and the formation of glutathione conjugates in human ovarian-carcinoma cell lines.
International journal of cancer. Journal international du cancer 1993;55(5):848-56.
1993: K J Mellish; Lloyd R Kelland; K R Harrap
In vitro platinum drug chemosensitivity of human cervical squamous cell carcinoma cell lines with intrinsic and acquired resistance to cisplatin.
British journal of cancer 1993;68(2):240-50.
1993: Lloyd R Kelland; G Abel; Mark J McKeage; M Jones; Phyllis M Goddard; M Valenti; BA Murrer; K R Harrap
Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Cancer research 1993;53(11):2581-6.
1993: W Gibson; G M Bisset; P R Marsham; Lloyd R Kelland; I R Judson; Ann L Jackman
The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells.
Biochemical pharmacology 1993;45(4):863-9.
1993: M Jones; J Siracky; Lloyd R Kelland; K R Harrap
Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
British journal of cancer 1993;67(1):24-9.
1992: S Y Loh; P Mistry; Lloyd R Kelland; G Abel; K R Harrap
Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
British journal of cancer 1992;66(6):1109-15.
1992: P Mistry; Lloyd R Kelland; S Y Loh; G Abel; BA Murrer; K R Harrap
Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
Cancer research 1992;52(22):6188-93.
1992: P R Twentyman; K A Wright; P Mistry; Lloyd R Kelland; BA Murrer
Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Cancer research 1992;52(20):5674-80.
1992: Lloyd R Kelland; P Mistry; G Abel; S Y Loh; CF O'Neill; BA Murrer; K R Harrap
Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
Cancer research 1992;52(14):3857-64.
1992: Lloyd R Kelland; P Mistry; G Abel; F Freidlos; S Y Loh; J J Roberts; K R Harrap
Establishment and characterization of an in vitro model of acquired resistance to cisplatin in a human testicular nonseminomatous germ cell line.
Cancer research 1992;52(7):1710-6.
1992: Lloyd R Kelland; BA Murrer; G Abel; C M Giandomenico; P Mistry; K R Harrap
Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
Cancer research 1992;52(4):822-8.
1992: Lloyd R Kelland; M Jones; G Abel; M Valenti; J Gwynne; K R Harrap
Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.
Cancer chemotherapy and pharmacology 1992;30(1):43-50.
1992: Lloyd R Kelland; G Abel
Comparative in vitro cytotoxicity of taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Cancer chemotherapy and pharmacology 1992;30(6):444-50.
1991: Mark J McKeage; J D Higgins; Lloyd R Kelland
Platinum and other metal coordination compounds in cancer chemotherapy. A commentary on the sixth international symposium: San Diego, California, 23-26th January 1991.
British journal of cancer 1991;64(4):788-92.
1991: P Mistry; Lloyd R Kelland; G Abel; S Sidhar; K R Harrap
The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
British journal of cancer 1991;64(2):215-20.
1991: K R Harrap; Lloyd R Kelland; M Jones; Phyllis M Goddard; R M Orr; S E Morgan; BA Murrer; M J Abrams; C M Giandomenico; T Cobbleigh
Platinum coordination complexes which circumvent cisplatin resistance.
Advances in enzyme regulation 1991;31():31-43.
1990: K R Harrap; M Jones; J Siracky; L A Pollard; Lloyd R Kelland
The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1990;1(1):65-76.
1989: C A Hills; Lloyd R Kelland; G Abel; J Siracky; A P Wilson; K R Harrap
Biological properties of ten human ovarian carcinoma cell lines: calibration in vitro against four platinum complexes.
British journal of cancer 1989;59(4):527-34.